Interferon and Risk for Drug-Seeking Behavior
The Internet Journal of Pain, Symptom Control and Palliative Care · 2009
DOI: 10.5580/1e26 ↗At a glance
Journal article in The Internet Journal of Pain, Symptom Control and Palliative Care, 2009.
Abstract (original language)
Interferon (IFN), a biological medication used to treat viral hepatitis and certain cancers, has clinically significant potential to cause a wide range of adverse neuropsychiatic effects. The spectrum ranges from agitation, aggression, insomnia and irritability, to suicidal thought and drug-seeking behavior (DSB). Out of a total population of 353 patients infected with hepatitis C virus (HCV), 132 patients at an inner city hepatitis clinic underwent treatment. Those treated were questioned at intake and on a regular basis for the initiation or increase of DSB. In addition, when warranted, patients were tested for the presence of drugs they were not prescribed. Over a four year period, ten patients (4 currently receiving treatment with IFN, 4 with prior treatment, and 2 who never received IFN) reported an increase in DSB. The danger of developing IFN-induced DSB appears to be relatively low (< 3%) in our patient population, and we also observed DSB in HCV patients who were not treated with IFN. To our knowledge, this is the first study of the incidence of DSB associated with IFN treatment for HCV that completely surveyed the HCV-treated population and used urine toxicology to verify illicit drug use.
Cite
APA
(2009). Interferon and Risk for Drug-Seeking Behavior. The Internet Journal of Pain, Symptom Control and Palliative Care. https://doi.org/10.5580/1e26
Vancouver
Interferon and Risk for Drug-Seeking Behavior. The Internet Journal of Pain, Symptom Control and Palliative Care. 2009. doi:10.5580/1e26
BibTeX
@article{euvimed2009,
title = {Interferon and Risk for Drug-Seeking Behavior},
journal = {The Internet Journal of Pain, Symptom Control and Palliative Care},
year = {2009},
doi = {10.5580/1e26}
}
EUVIMED